GLP-1 Agonists are serious medications of which there are no long-term studies of, for obvious reasons. However, there are very, very serious side-effects showing up, sarcopenia being most common, with osteoporosis increasingly showing up. Sarcopenia, especially alongside osteoporosis, is one of the three leading causes of death in older people. It's not a little thing to brush off, losing muscle and bone density is incredibly serious. There is also the issue of cardiac shrinkage in animal testing, which is incredibly serious if we see it in humans.
These medications really need to be used sparingly, in cases where the risk of side-effects is the lesser risk to the patient, not for people who don't feel like making the effort to look how they'd like. As for the cravings and having to weigh up whether or not we should eat something. That's life, the people who don't feel like that are rare. Most people love delicious food, and the social side of eating and have to weigh up whether of not they'll have x now, versus y later. Tall, naturally lean people, especially men, and/or is they are very active, are the only people who can eat whatever they want, whenever. There are also some people who just aren't especially food motivated, but that comes with it's own drawback of never getting to derive great pleasure from food.
If the drugs can be adapted so side-effects are mitigated, and they possibly could be if used as a tool in a multi-pronged approach, where resistance training is done to ensure muscle and bone loss don't happen. Alongside other measures, and everyone could take them and maintain a healthy weight, that would be fantastic. But until we can be sure that 'the cure isn't worse than the disease,' it would be foolhardy to roll them out as some here think they should be. Already there is a huge class action lawsuit happening in the US, with over 2k litigants, as of the start of this month, claiming serious side effects. This is without doubt going to grow massively in the coming years. It's possibly that GLP1 agonists will become more widespread a decade from now, but it's equally possible that they will be looked back on with horror.